We are live on ! Find out more
CATX icon

Perspective Therapeutics

29 hedge funds and large institutions have $2.99M invested in Perspective Therapeutics in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more capital invested

Capital invested by funds: $1.58M → $2.99M (+$1.41M)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

0.22% more ownership

Funds ownership: 0.63%0.86% (+0.22%)

3% less funds holding

Funds holding: 3029 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
29
Holders Change
-1
Holders Change %
-3.33%
% of All Funds
0.66%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
5
Reduced
3
Closed
4
Calls
Puts
Net Calls
Net Calls Change

CATX Hedge Fund Activity: Q3 2018 in Review

29 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q3 2018, worth a combined $2.99M — up 89% from $1.58M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CATX and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $1.07M. The largest seller was Raymond James Financial Services Advisors, cutting an estimated $6.96K.

  • 29 institutional investors held Perspective Therapeutics (CATX) as of Q3 2018, down from 30 in Q2 2018.
  • Funds reported $2.99M of Perspective Therapeutics stock for Q3 2018, up 89% quarter-over-quarter.
  • 3 funds opened new Perspective Therapeutics positions in Q3 2018 and 4 closed out, a net change of -1 holder.
  • The largest Perspective Therapeutics buyer in Q3 2018 was Sabby Management, an estimated $1.07M added.
  • The largest Perspective Therapeutics seller in Q3 2018 was Raymond James Financial Services Advisors, an estimated $6.96K sold.

Based on aggregated 13F filings for Q3 2018.